| |
|
|
Session 27
Oral Abstract Presentations Antiretroviral Drug Resistance Thursday 10 - 11:45 am Ballroom C |
| Moderators: | Walid Heneine CDC, Atlanta, GA and Sabine Yerly Hosp Cantonal Univ, Geneva, Switzerland |
| 10:00 140 | The Potential for Cross Resistance Between S-1360, L-870810 and Other Structurally Diverse Inhibitors of HIV-1 Integrase Strand Transfer Daria Hazuda*, The Integrase Inhibitor Discovery Team Merck Res Labs, West Point, PA |
| 10:15 141 | Baseline and On-treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks M L. Greenberg*1, T Melby1, P Sista1, R DeMasi1, N Cammack2, M Salgo3, J Whitcomb4, C Petropoulos4, TJ Matthews1 1Trimeris Inc, Durham, NC,; 2Roche BioSci, Palo Alto, CA; 3Hoffmann-La Roche, Inc, Nutley, NJ; and 4ViroLogic, San Francisco, CA |
| 10:30 143 | Effect of Amprenavir Hyper-susceptibility on the Response to APV/Ritonavir-based Therapy in ART-experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-week Data R Schooley*1, R Haubrich2, M Thompson3, D Margolis4, S Schneider5, D Richman2, K Pappa6, L Yau6, S Hessenthaler6, J Hernandez6 1Univ of Colorado, Denver; 2Univ of California at San Diego; 3AIDS Res Consortium of Atlanta, GA; 4Dallas VA Med Ctr, TX; 5Living Hope Clin Trials, Long Beach, CA; and 6GlaxoSmithKline, Research Triangle Park, NC |
| 10:45 144 | Novel Drug Resistance Profiles in Non-B Subtype HIV-1 Infections D. Turner*1, B. Brenner1, B. Spira1, J. Schapiro2, M. Songok1, M. A. Wainberg1 1McGill AIDS Ctr, Lady Davis Inst, Jewish Gen Hosp, Montreal, Canada and 2Stanford Univ Sch of Med, Palo Alto, CA |
| 11:00 145 | Are Drug-resistance Variants Transmitted with Lower Efficiency than Wild-type? S Yerly*1, S Jost1, A Telenti2, M Flepp3, L Kaiser1, J P Chave4, P Vernazza5, M Battegay6, H Furrer7, C Michon8, P Burgisser2, M Rickenbach9, M Gebhardt10, B Hirschel1, L Perrin1 1Geneva Univ Hosp Switzerland; 2Lausanne Univ Hosp Switzerland; 3Zurich Univ Hosp, Switzerland; 4Lausanne La Source Hosp, Switzerland; 5St Gall Univ Hosp, Switzerland; 6Basel Univ Hosp, Switzerland; 7Bern Univ Hosp, Switzerland; 8Annecy Hosp, France; 9Swiss HIV Cohort Study, Lausanne, Switzerland; and 10Swiss Federal Office of Publ Hlth, Bern, Switzerland |
| 11:15 146 | Viral and Immune Correlates of Discordant CD4/VL Responses to NNRTI-based HAART and Comparison to a Discordant Cohort Receiving Protease Inhibitor-Based HAART D. Linden1, S. Sufka1, G. Ferrari1, S. Fiscus2, T. Wrin3, V. Gryszowka1, B. Exley1, K. Weinhold1, N. Hellman3, C. Petropoulous3, C. Hicks*1 1Duke Univ Med Ctr, Durham, NC; 2Univ of North Carolina, Chapel Hill; and 3Virologic, Inc, South San Francisco, CA |
| 11:30 146lb | Factors Affecting CD4 Count Slope in Patients with Stable Viral Load Following Three Class Virologic Failure: The PLATO Collaboration Bruno Ledergerber*1, Jens D. Lundgren2, Gregory P. Fusco3, Rainer Weber1, Ferdinand Wit4, Francesco Castelli5, Schlomo Staszewski6, Robert Hogg7, A. Sarah Walker8, Kathy Petoumenos9, Antonella d'Arminio Monforte10, Cristina Mussini11, Fiona Lampe12, M. John Gill13, Andrew N. Phillips12 1Univ Hosp Zurich, Switzerland; 2Hvidovre Univ Hosp, Hvidovre, Denmark; 3GSK, Research Triangle Park, NC; 4Academic Medical Center, Amsterdam, The Netherlands; 5Univ of Brescia, Brescia, Italy; 6J W Goethe-Univ Frankfurt, Germany; 7Univ of British Columbia, Vancouver, Canada; 8MRC Clinical Trials Unit, London, UK; 9Natl Centre in HIV Epidemiol and Clin Research, UNSW, Australia; 10Univ Milan, Milan, Italy; 11Clin Infect Dis, Modena, Italy; 12Royal Free & Univ Coll Med Sch, London, UK; and 13South Alberta Clin, Calgary, Canada |